Covid-19 pandemic: 80% of Indians may be vaccinated by March 2022

Vaccine production should ramp up, June onwards, given that manufacturers are boosting capacities

Covid-19 pandemic: 80% of Indians may be vaccinated by March 2022
US government is likely to ease export restrictions on vaccines and raw materials following the vaccination of significant native populace
Sohini Das
2 min read Last Updated : May 12 2021 | 12:21 AM IST
About 40 per cent of India’s adult population will be fully vaccinated by November, largely through indigenous vaccine production, according to a recent Yes Securities report. By January 2022, the analysts estimate, another 20 per cent is likely to be vaccinated, thereby covering 60 per cent of the adult population. Yes Securities further estimated that by the end of this fiscal year (March 2022), about 80 per cent of the adult population will be vaccinated.

"It is pertinent to note that the vaccination threshold for herd immunity, as defined by one of WHO’s chief scientists, is 60‐70 per cent of the total population," the analysts noted. 

“India’s teething troubles of vaccination coverage are likely to persist over the next month, owing to raw material scarcity for domestic manufacture. Shortage, if severe, can dent vaccination drive with 75 million of the population to be prioritised for second dose (who will be due after stipulated seven weeks of first dose), bringing the first dose to a halt and derailing the future vaccination run‐rate,” the analysts cautioned.

However, vaccine production should ramp up, June onwards, given that manufacturers are boosting capacities and the US government is likely to ease export restrictions on vaccines and raw materials following the vaccination of significant native populace, over the next 45 days. Considering that India's adult population of 1 billion will account for the largest market for US vaccines, it estimated that 20‐25 per cent of US vaccine exports will head to India.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineIndia vaccinationHealth Ministry

Next Story